Basic Information
| LncRNA/CircRNA Name | FEZF1-AS1 |
| Synonyms | NR_036484 |
| Region | GRCh38_7:122303658-122310077 |
| Ensemble | ENSG00000230316 |
| Refseq | NR_036484 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot |
| Sample | The cells: WPMY-1 (control cells), 22RV1, PC-3, DU145, and LNCaP cells, PC specimens and matched normal samples |
| Expression Pattern | up-regulated |
| Function Description | FEZF1-AS1 expressions were distinctly reduced in human PCa tissues and cell lines compared with their non-tumor counterparts, and its higher levels were strongly associated with lymph node metastasis (p=0.012) and Angiolymphatic invasion (p=0.022). Then, Kaplan-Meier assays showed that patients with higher expressions of FEZF1-AS1 were shown to predict unfavorable overall survival. Cox proportional hazards risks assays revealed that FEZF1- AS1 acted as an independent prognostic factor for PCa. Functional investigations suggested that knockdown of FEZF1-AS1 could suppress cells proliferation, trigger late apoptosis, and inhibit cells invasion and migration. Mechanistic assays demonstrated that FEZF1-AS1 exhibited its tumor-promotive roles by activating the Notch signaling pathway. |
| Pubmed ID | 31298365 |
| Year | 2019 |
| Title | Highly expressed long non-coding RNA FEZF1- AS1 promotes cells proliferation and metastasis through Notch signaling in prostate cancer |
External Links
| Links for FEZF1-AS1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |